These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 12132459)

  • 21. One size does not fit all.
    Soloway B; Fichtenbaum CJ
    AIDS Clin Care; 2001 Oct; 13(10):92-3. PubMed ID: 11590922
    [No Abstract]   [Full Text] [Related]  

  • 22. Didanosine plus stavudine with or without hydroxyurea in HIV-1-infected patients: 1 year follow-up. Swiss HIV Cohort Study.
    Rutschmann OT; Opravil M; Iten A; Malinverni R; Vernazza PL; Bucher H; Bernasconi E; Perrin LH; Yerly S; Hirschel B
    Antivir Ther; 1998; 3 Suppl 4():65-7. PubMed ID: 10723515
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hydroxyurea plus didanosine as maintenance therapy for HIV-infected patients on long-term successful highly active antiretroviral therapy.
    Barreiro P; de Mendoza C; Camino N; García-Benayas T; Blanco F; Núñez M; González-Lahoz J; Soriano V
    HIV Clin Trials; 2003; 4(6):361-71. PubMed ID: 14628279
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hydroxyurea: what it is. New Mexico AIDS InfoNet.
    Newsline People AIDS Coalit N Y; 1998 Mar; ():15. PubMed ID: 11367449
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of primary HIV infection: a pilot study of stavudine and didanosine plus nevirapine with or without hydroxyurea.
    Zala C; Salomón H; Cahn P
    Antivir Ther; 1999; 4 Suppl 3():95-9. PubMed ID: 16021880
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Report on adherence from the XIV International AIDS Conference in Barcelona.
    Sabundayo BP
    Hopkins HIV Rep; 2002 Nov; 14(6):8-9, 12. PubMed ID: 12491992
    [No Abstract]   [Full Text] [Related]  

  • 27. Who gets treatment and...side effects.
    TreatmentUpdate; 2002 Dec; 14(9):2-3. PubMed ID: 12593382
    [No Abstract]   [Full Text] [Related]  

  • 28. The current status of antiretroviral therapy in Africa.
    Bray DH
    J HIV Ther; 2006 Mar; 11(1):7-10. PubMed ID: 16706249
    [No Abstract]   [Full Text] [Related]  

  • 29. Pharmacokinetics, safety and anti-human immunodeficiency virus (HIV) activity of hydroxyurea in combination with didanosine.
    Luzzati R; Di Perri G; Fendt D; Ramarli D; Broccali G; Concia E
    J Antimicrob Chemother; 1998 Oct; 42(4):565-6. PubMed ID: 9818769
    [No Abstract]   [Full Text] [Related]  

  • 30. Report from the 15th Retrovirus Conference. Parsing the options from comparative trials of initial antiretroviral therapy.
    Feinberg J
    AIDS Clin Care; 2008 Apr; 20(4):27. PubMed ID: 19256087
    [No Abstract]   [Full Text] [Related]  

  • 31. Amping amprenavir with ritonavir.
    TreatmentUpdate; 2001; 12(12):10. PubMed ID: 11570075
    [No Abstract]   [Full Text] [Related]  

  • 32. Hydroxyurea and didanosine long-term treatment prevents HIV breakthrough and normalizes immune parameters.
    Lori F; Rosenberg E; Lieberman J; Foli A; Maserati R; Seminari E; Alberici F; Walker B; Lisziewicz J
    AIDS Res Hum Retroviruses; 1999 Oct; 15(15):1333-8. PubMed ID: 10515148
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of hydroxyurea in heavily pretreated patients with HIV infection.
    Hermans P; De Wit S; Sommereijns B; O'Doherty E; Clumeck N
    Antivir Ther; 1999; 4 Suppl 3():19-22. PubMed ID: 16021867
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dethroning AZT.
    Gilden D; Falkenberg J; Torres G
    GMHC Treat Issues; 1997 Feb; 11(2):10-3. PubMed ID: 11364106
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Switching antiretroviral therapy.
    Highleyman L
    BETA; 2006; 18(4):17-29. PubMed ID: 17019787
    [No Abstract]   [Full Text] [Related]  

  • 36. [Viral load and CD4+ lymphocyte count in the era of highly active antiretroviral therapy].
    Martín JC; Fernández P; Soriano V; Martínez P; González-Lahoz J
    Med Clin (Barc); 2000 Jun; 115(3):118. PubMed ID: 10965488
    [No Abstract]   [Full Text] [Related]  

  • 37. A randomized study of the safety and antiretroviral activity of hydroxyurea combined with didanosine in persons infected with human immunodeficiency virus type 1. American Foundation for AIDS Research Community-Based Clinical Trials Network.
    Hellinger JA; Iwane MK; Smith JJ; Fleishman AN; Torres RA; Schrader S; Perez G; Cohen CJ; Skowron G; Giordano MF; Accetta G; Cooper EC; Frost KR
    J Infect Dis; 2000 Feb; 181(2):540-7. PubMed ID: 10669337
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antiretroviral update from the 46th ICAAC.
    Gallant JE
    Hopkins HIV Rep; 2007 Jan; 19(1):1-3, 12. PubMed ID: 17569167
    [No Abstract]   [Full Text] [Related]  

  • 39. A randomized trial to investigate the recycling of stavudine and didanosine with and without hydroxyurea in salvage therapy (RESTART).
    Stebbing J; Nelson M; Orkin C; Mandalia S; Bower M; Pozniak A; Gazzard B
    J Antimicrob Chemother; 2004 Mar; 53(3):501-5. PubMed ID: 14762056
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Absence makes the HAART grow fonder.
    Gilden D
    GMHC Treat Issues; 1999 Feb; 13(2):1-4. PubMed ID: 11366113
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.